Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
(S)-Ketamine OTF vs IV in Healthy Participants
NCT03808259Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esketamine in treatment-resistant depression (TRD) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinician-Administered Dissociative States Scale Total Score, Number of Participants with Vital Sign Abnormalities and 4 more. Started Dec 2018; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03808259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808259.